Skip to main content

$0.062 0.002 (3.33%)

High

$0.06

Low

$0.06

Trades

18

Turnover

$32,113

Volume

526,676
30 June 2023 at 3:59pm
Register to track DXB and receive email alerts.

Successful Completion of DSMB Review of Phase 3 FSGS Trial

StockBot

416,823 posts

DXB released this announcement to the ASX on 9 February 2023, 9:04. The announcement is marked as price sensitive, and is 4 page(s) in length and 339.4kb in size.

You can view all announcements from DXB and see how they appear on a price chart on the announcements page.

At the date of this announcement, DXB was 0.058% short sold according to ASIC data. It was ranked the 509th most shorted stock on the ASX. It is now ranked as the 444th most shorted stock on the ASX with 0.114% of total shares short sold as of the latest reported data (26 May 2026).

Other Recent Announcements from DXB
Application for quotation of securities - DXB 29 June 2023, 9:01
Application for quotation of securities - DXB 29 June 2023, 9:00
Application for quotation of securities - DXB 29 June 2023, 8:59
Successful Completion of DSMB Review of Phase 3 FSGS Trial 9 February 2023, 9:04
Quarterly Appendix 4C and Activities Report 31 January 2023, 8:45
FDA Confirms Inclusion of Paediatrics in ACTION3 Study 12 January 2023, 9:16
Final Director's Interest Notice 28 December 2022, 10:29
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track DXB and receive email alerts.